Skip to main content
Premium Trial:

Request an Annual Quote

OSI Pharmaceuticals Signs Agreement to Evaluate Horizon Discovery Cell Lines

NEW YORK (GenomeWeb News) – The Cambridge, UK-based translational genomics company Horizon Discovery announced today that it has signed a non-exclusive commercial agreement with OSI Pharmaceuticals. Under the agreement, OSI will evaluate nine of Horizon’s X-MAN cell lines and matched cells with normal genetic backgrounds for 12 months, starting this month.
OSI intends to characterize the cell lines and to use them for testing both known and internally developed compounds directed at genotypes of interest. The company will share key datasets with Horizon during that evaluation period. In addition, Horizon and OSI will reportedly work together to generate new data for research areas in which both companies are interested.
The X-MAN lines are isogenic human cell lines representing genetically defined in vitro models of human cancer. The cancerous and non-cancerous cell types were developed to aid in drug discovery and help assess treatments in clinical trials.
Financial terms of the agreement were not disclosed.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.